Vaccine-boosted convalescent plasma therapy for patients with immunosuppression and COVID-19
TO THE EDITOR:
TO THE EDITOR:
PURPOSE Biliary tract cancers (BTCs) are aggressive cancers that carry a poor prognosis. An enhanced understanding of the immune landscape of anatomically and molecularly defined…
Background Oncogenic BRAF mutations can be categorized into three classes (I, II and III) based on their distinct structural and signaling properties. BRAF inhibitors are…
Key Points. RAS/RAF mutations are present in up to 61% of patients with multiple myelomaMost of them are subclonal, in agreement with a secondary event
Key Points. Quantification of the primary myeloma cell surface proteome enables unbiased discovery of novel therapeutic targets.Targeting SEMA4A using an a
Amplification of chromosome 1q (chr1q-amp) is an adverse prognostic feature in multiple myeloma (MM). In this Plenary paper, Trasanidis and colleagues perf
As SARS-CoV-2 evolves, new variants of concern (VOCs) have emerged that evade available anti-spike monoclonal antibodies, particularly among immunosuppressed patients. However, high-titer COVID-19 convalescent plasma…
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19.
Click on the article title to read more.
EHA Library; Müller-Tidow C. Jun 10 2022; 357146;